Home The Word Brain My Amedeo FAQ Privacy About


Hanzi Hunter

Learning 500 Chinese characters in 30 days is possible.

Abstract • About

  Breast Cancer

  Free Subscription


23.02.2026

8 Ann Surg Oncol
4 BMC Cancer
1 Breast Cancer
3 Breast Cancer Res
4 Breast Cancer Res Treat
2 Cancer
2 Cancer Lett
1 Cell
2 Clin Breast Cancer
1 Eur Radiol
1 Int J Oncol
1 J Clin Invest
3 J Natl Cancer Inst
2 Lancet Oncol
1 Nat Rev Clin Oncol
2 Nature
2 NPJ Breast Cancer
2 Oncogene
1 Oncol Rep
1 Oncology (Williston Park)
1 PLoS Comput Biol
2 PLoS One
2 Proc Natl Acad Sci U S A


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Ann Surg Oncol

  1. AYUB S, Marra A, Liu Y, Postlewait LM, et al
    Rurality and Income on Breast Cancer Outcomes: An Analysis of the SEER Database.
    Ann Surg Oncol. 2026 Feb 19. doi: 10.1245/s10434-026-19254.
    PubMed         Abstract available

  2. RODRIGUEZ L, Wu R, Kassi A, Ishikawa T, et al
    High PARP7 Expression is Associated with Higher Estrogen Response and Immune Suppression but Less Cell Proliferation and Better Survival in Breast Cancer.
    Ann Surg Oncol. 2026 Feb 19. doi: 10.1245/s10434-026-19133.
    PubMed         Abstract available

  3. KINOSHITA T, Takayama S, Fujisawa T, Watanabe K, et al
    Radiofrequency Ablation for Early Stage Breast Cancer as a Potential Alternative to Partial Mastectomy: 5-Year Results from the Multiple-Center, Single-Arm, Phase 3 RAFAELO Study (NCCH1409).
    Ann Surg Oncol. 2026 Feb 18. doi: 10.1245/s10434-026-19220.
    PubMed         Abstract available

  4. PUJOL N, Gal J, Gautier M, Rizzi Y, et al
    Second Ipsilateral Breast Cancer Event: True Recurrence, New Primary, or True Recurrence Like? : Breast Cancer Local Recurrence.
    Ann Surg Oncol. 2026 Feb 18. doi: 10.1245/s10434-026-19131.
    PubMed         Abstract available

  5. SCHRANK Z, Selfridge JM
    ASO Author Reflections: Do Older Triple-Negative Breast Cancer Patients Respond Differently to Neoadjuvant Chemoimmunotherapy?
    Ann Surg Oncol. 2026 Feb 18. doi: 10.1245/s10434-026-19299.
    PubMed        

  6. ABDULLA HA, McGarry J, Kaczorowska R, Grealish A, et al
    ASO Visual Abstract: Oncological Outcomes of Sentinel Lymph Node Biopsy Versus Targeted Axillary Dissection in Node-Positive Breast Cancer Patients After Neoadjuvant Chemotherapy: A Systematic Review and Meta-analysis.
    Ann Surg Oncol. 2026 Feb 18. doi: 10.1245/s10434-026-19273.
    PubMed        

  7. JAYASWAL RP
    Letter Comments on: Differences in Breast Cancer Care Between Rural Women Undergoing Treatment at a Referral Center and Those Treated Locally.
    Ann Surg Oncol. 2026 Feb 17. doi: 10.1245/s10434-026-19258.
    PubMed        

  8. RYU HH, Lee YJ, Yoo TK, Kim J, et al
    Clinical Utility of Oncotype DX Testing in Synchronous Bilateral and Unilateral Multifocal Breast Cancer.
    Ann Surg Oncol. 2026 Feb 16. doi: 10.1245/s10434-026-19243.
    PubMed         Abstract available


    BMC Cancer

  9. DENG Y, Huang W, Zeng T, Gao Y, et al
    CDK4/6 inhibitors combined with fulvestrant for the treatment of HR+/HER2-advanced or metastatic breast cancer: a Bayesian network meta-analysis.
    BMC Cancer. 2026 Feb 17. doi: 10.1186/s12885-026-15713.
    PubMed        

  10. BROWNSON-SMITH R, Carr J, Orange ST, Cresti N, et al
    Longitudinal assessment of chemotherapy-induced peripheral neuropathy in women undergoing taxane-based treatment for breast cancer: a prospective observational study.
    BMC Cancer. 2026 Feb 19. doi: 10.1186/s12885-026-15750.
    PubMed        

  11. EDET B, Sarimiye FO, Essien E, Lu B, et al
    A cross-sectional study of coping strategies among a sample of women with breast cancer in South-South, Nigeria.
    BMC Cancer. 2026 Feb 19. doi: 10.1186/s12885-026-15770.
    PubMed        

  12. HOSSAIN I, Ivy SC, Islam MS, Shahriar M, et al
    Evaluation of ERCC4 (XPF) gene rs6498486 polymorphism and its potential role in breast cancer risk among Bangladeshi women.
    BMC Cancer. 2026 Feb 17. doi: 10.1186/s12885-026-15739.
    PubMed        


    Breast Cancer

  13. PANG J, Huang B, Yan W, He H, et al
    Prognostic model for pulmonary metastasis in patients with HER2-positive breast cancer: a population-based study.
    Breast Cancer. 2026 Feb 16. doi: 10.1007/s12282-026-01836.
    PubMed        


    Breast Cancer Res

  14. ALDRICH MB, McWain ME, Shaitelman SF, Kuhns RE, et al
    Lymphatic pumping failure in the arm precedes dermal backflow and breast cancer-related lymphedema.
    Breast Cancer Res. 2026 Feb 17. doi: 10.1186/s13058-026-02231.
    PubMed        

  15. BREMER T, Mittal K, Shah C, Vicini F, et al
    Development and cross-validation of a novel multi-omic assay to assess locoregional recurrence risk and adjuvant therapy benefit in early-stage hormone receptor positive invasive breast cancer patients.
    Breast Cancer Res. 2026 Feb 18. doi: 10.1186/s13058-026-02237.
    PubMed        

  16. DEHGHAN MANSHADI M, Hashemi F, Safaei S, Golshahi H, et al
    Prophylactic and therapeutic CSC-based vaccination reduced tumor growth, metastasis and enhanced survival in mouse model of breast cancer.
    Breast Cancer Res. 2026 Feb 19. doi: 10.1186/s13058-026-02242.
    PubMed        


    Breast Cancer Res Treat

  17. TSE SSW, Wong HCY, Charbonneau F, Cao JQ, et al
    Cost-effectiveness analysis of Mepitel Film for prevention of acute radiation dermatitis in breast cancer: a Canadian healthcare perspective.
    Breast Cancer Res Treat. 2026;216:10.
    PubMed         Abstract available

  18. SOYANO MULLER AE, Goodridge DN, Mo Q, Whiting J, et al
    Neoadjuvant therapy with an aromatase inhibitor and durvalumab in postmenopausal patients with hormone receptor-positive breast cancer.
    Breast Cancer Res Treat. 2026;216:11.
    PubMed         Abstract available

  19. SHINN E, Zahrieh D, DeMichele A, Zdenkowski N, et al
    Correction: Impact of adding palbociclib on treatment adherence to ongoing adjuvant endocrine treatment in the global randomized PALLAS randomized trial in patients with early breast cancer.
    Breast Cancer Res Treat. 2026;216:12.
    PubMed        

  20. VASIGH M, Williams AD, Hasler JS, Aggon A, et al
    The role of regional nodal irradiation in clinically node-positive breast cancer patients who undergo neoadjuvant chemotherapy and breast-conserving surgery.
    Breast Cancer Res Treat. 2026;216:14.
    PubMed         Abstract available


    Cancer

  21. LAWRENCE L
    TROP2-targeted ADCs demonstrate survival benefit for patients with advanced triple-negative breast cancer: Almost a 3-month improvement was seen in median PFS for patients assigned to sacituzumab govitecan in comparison to those assigned to chemothera
    Cancer. 2026;132:e70249.
    PubMed        

  22. LIPSCOMB J, Kimmick GG, Wilson JF, Currey A, et al
    Receipt of guideline-concordant local and chemotherapy-based systemic therapy for patients with triple-negative breast cancer: 10-year survival outcomes in a multi-state population-based analysis.
    Cancer. 2026;132:e70267.
    PubMed         Abstract available


    Cancer Lett

  23. ZHAO Z, Jia W, Li Z, Shi S, et al
    Targeting the SIN1 mediated TTK/LDHA-H3K18la-GLUT3 Axis Disrupts Metabolic-Epigenetic Crosstalk and Suppresses Progression in Hyperglycolytic Breast Cancer.
    Cancer Lett. 2026 Feb 16:218328. doi: 10.1016/j.canlet.2026.218328.
    PubMed         Abstract available

  24. XUE X, Ji D, Xue L, Tan Y, et al
    Spatially Resolved Transcriptomics Identifies Tumor-Stroma-Immune Networks and Therapeutic Targets in Endocrine-Resistant Advanced Breast Cancer Treated with Everolimus+Letrozole: Insights from the MIRACLE Trial.
    Cancer Lett. 2026 Feb 18:218327. doi: 10.1016/j.canlet.2026.218327.
    PubMed         Abstract available


    Cell

  25. BARKI D, Eilat N, Scherz-Shouval R
    Striking a nerve: Sensory neurons orchestrate ECM remodeling and immune exclusion in TNBC.
    Cell. 2026;189:993-994.
    PubMed         Abstract available


    Clin Breast Cancer

  26. MIYASHITA H, Aoshima K
    Predicting Skeletal-Related Events in Bone Metastasis from Advanced Breast Cancer Using Machine Learning.
    Clin Breast Cancer. 2026 Jan 12:S1526-8209(26)00004.
    PubMed         Abstract available

  27. AU LJ, Zhang YN, Yeung K, Cheung KL, et al
    Efficacy and Safety of Neoadjuvant Dual HER2-Targeted Therapy in Older and Younger Patients With HER2-Positive Early Breast Cancer: A Real-World Retrospective Analysis.
    Clin Breast Cancer. 2026;26:84-93.
    PubMed         Abstract available


    Eur Radiol

  28. EOM HJ, Kim HH, Kim SH, Gwon HY, et al
    Implant-displacement views alone for breast cancer screening in women with implants: a multicenter retrospective study.
    Eur Radiol. 2026 Feb 20. doi: 10.1007/s00330-026-12374.
    PubMed         Abstract available


    Int J Oncol

  29. LIU J, Du H, Shi Y
    Role and underlying mechanisms of miR?200 family in breast cancer (Review).
    Int J Oncol. 2026;68:43.
    PubMed         Abstract available


    J Clin Invest

  30. YU L, Rivas C, Liu F, Shen Y, et al
    Inflammation- and resolution-programmed myeloid circuits govern therapeutic resistance in epithelial and mesenchymal triple-negative breast cancer.
    J Clin Invest. 2026 Feb 17:e198815. doi: 10.1172/JCI198815.
    PubMed         Abstract available


    J Natl Cancer Inst

  31. DANIELSSON O, Dar H, Nordenskjold A, Perez-Tenorio G, et al
    Tamoxifen therapy benefit in luminal A and B breast cancer with 20-year follow-up.
    J Natl Cancer Inst. 2026 Feb 19:djag049. doi: 10.1093.
    PubMed         Abstract available

  32. TICKLE A, Offman J, North B, Jorgensen SF, et al
    Improved stage-specific survival in screen-detected breast cancer in Denmark: a cohort study.
    J Natl Cancer Inst. 2026 Feb 19:djaf377. doi: 10.1093.
    PubMed         Abstract available

  33. KORIC A, Bennett DL, Boulos F, Colditz GA, et al
    Subsequent breast cancer risk after benign biopsy in racially diverse women: Siteman Cancer Center.
    J Natl Cancer Inst. 2026 Feb 16:djag048. doi: 10.1093.
    PubMed         Abstract available


    Lancet Oncol

  34. LOUIS FM, van der Voort A, van Ramshorst MS, Daletzakis A, et al
    MRI-based personalisation of neoadjuvant chemotherapy duration in HER2-positive early breast cancer (TRAIN-3): primary results from a multicentre, single-arm, phase 2 study.
    Lancet Oncol. 2026 Feb 16:S1470-2045(25)00707.
    PubMed         Abstract available

  35. NADER-MARTA G, Mayer EL
    Towards response-adapted neoadjuvant breast cancer treatment.
    Lancet Oncol. 2026 Feb 16:S1470-2045(25)00767.
    PubMed        


    Nat Rev Clin Oncol

  36. KILLOCK D
    CDK4/6 inhibition provides additional efficacy in HER2(+), HR(+) breast cancer.
    Nat Rev Clin Oncol. 2026 Feb 17. doi: 10.1038/s41571-026-01133.
    PubMed        


    Nature


  37. Personalized mRNA vaccine induces strong, durable immunity in hard-to-treat breast cancer.
    Nature. 2026 Feb 18. doi: 10.1038/d41586-026-00477.
    PubMed        

  38. HAN Y, Ma Y, Pei M, Yin S, et al
    Intratumoural vaccination via checkpoint degradation-coupled antigen presentation.
    Nature. 2026;650:736-747.
    PubMed         Abstract available


    NPJ Breast Cancer

  39. XU T, Gu Q, Li S, Zhang L, et al
    Phase II trial of anlotinib-chemotherapy combination in pretreated HER2-negative metastatic breast cancer: therapeutic efficacy and proteomic biomarker profiling.
    NPJ Breast Cancer. 2026 Feb 17. doi: 10.1038/s41523-026-00914.
    PubMed         Abstract available

  40. ZELS G, Van Baelen K, Chang AC, Pabba A, et al
    Clinical and histopathological characterization of metastatic lobular breast cancer: lessons learned from post-mortem tissue donation programs.
    NPJ Breast Cancer. 2026 Feb 20. doi: 10.1038/s41523-026-00912.
    PubMed         Abstract available


    Oncogene

  41. MA L, Sheng X, Wang L, Wan X, et al
    KDM6A alternative splicing induced by 25(OH)D inhibits breast cancer cell stemness through repressing TRAP1 transcription.
    Oncogene. 2026 Feb 17. doi: 10.1038/s41388-026-03694.
    PubMed         Abstract available

  42. SZYMANSKI L, Schenk T, Lawinski M, Brioli A, et al
    Association of retinoids, retinoic acid receptors and epigenetics in breast cancer.
    Oncogene. 2026 Feb 20. doi: 10.1038/s41388-026-03699.
    PubMed         Abstract available


    Oncol Rep

  43. YUAN Z, Sanders AJ, Ye L, Wang Y, et al
    [Retracted] Knockdown of human antigen R reduces the growth and invasion of breast cancer cells in vitro and affects expression of cyclin D1 and MMP?9.
    Oncol Rep. 2026;55:73.
    PubMed         Abstract available


    Oncology (Williston Park)

  44. POLAND S, de Oliveira Andrade Md M, Nanda R
    Advances in Immunotherapy for Breast Cancer.
    Oncology (Williston Park). 2026;40:8-15.
    PubMed         Abstract available


    PLoS Comput Biol

  45. WANG Y, Zang C, Li Z, Guo CC, et al
    A comparative study of statistical methods for identifying differentially expressed genes in spatial transcriptomics.
    PLoS Comput Biol. 2026;22:e1013956.
    PubMed         Abstract available


    PLoS One

  46. ALQAHTANI S, Alqahtani K, Alshomrani F, AlQahtani K, et al
    AdaptiveInvolutionNet: Spatially-adaptive involution with channel-wise attention for breast MRI tumor classification.
    PLoS One. 2026;21:e0340808.
    PubMed         Abstract available

  47. XU F, Xie S, Li Q, Zhong X, et al
    The effect of self-concealment on post-traumatic stress symptoms in breast cancer patients: The mediating role of experiential avoidance.
    PLoS One. 2026;21:e0342971.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  48. LOU KL, Bai JW, Liu HT, Lin LL, et al
    TROP2-targeted NIR-II fluorescence imaging for visualizing surgical margins and metastatic sentinel lymph nodes in breast cancers.
    Proc Natl Acad Sci U S A. 2026;123:e2519420123.
    PubMed         Abstract available

  49. YAN P, Bui T, Rojas Jimenez E, Kuang Y, et al
    Aging-associated differences in mammary tumor-initiating populations and immune evasion pathways in breast cancer.
    Proc Natl Acad Sci U S A. 2026;123:e2523254123.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.

Privacy / Datenschutzerklärung | Imprint / Impressum